Please login to the form below

Not currently logged in
Email:
Password:

CAR-T therapy

This page shows the latest CAR-T therapy news and features for those working in and with pharma, biotech and healthcare.

Celgene boosts CAR-T stake again with Bluebird Bio deal

Celgene boosts CAR-T stake again with Bluebird Bio deal

Mere weeks after completing its acquisition of CAR-T specialist Juno, Celgene has added to its cell therapy pipeline with another clinical-stage CAR-T candidate from Bluebird Bio. ... It could also receive additional, undisclosed milestones if the CAR-T

Latest news

  • Novartis gets speedy reviews for new Kymriah filings Novartis gets speedy reviews for new Kymriah filings

    Novartis’plans to expand the use of its CAR-T therapy Kymriah look rosier after the FDA and EMA both said they would carry out speedy reviews of new indications. ... CAR-T is a new approach to immuno-oncology that uses modified versions of a patient's

  • Spark’s Luxturna becomes US’s first approved gene therapy Spark’s Luxturna becomes US’s first approved gene therapy

    two CAR-T therapies for blood cancers which involve genetically modifying cells outside the body. ... Novartis’first-approved CAR-T therapy Kymriah (tisagenleucel) has been priced at $475, 000 per course in the US, but a recent Bloomberg report

  • Gilead adds to CAR-T assets with Cell Design Labs buyout Gilead adds to CAR-T assets with Cell Design Labs buyout

    One CDL approach - called synNotch - is designed to require two antigens rather than one to active the CAR-T cell, potentially making the therapy more tumour-specific. ... The acquisition was announced just before the American Society of Haematology (ASH)

  • Novartis files CAR-T therapy CTL109 in Europe Novartis files CAR-T therapy CTL109 in Europe

    Novartis files CAR-T therapy CTL109 in Europe. Analysts predict Kymriah could become a $1bn-plus product in Europe. ... Fresh from the first regulatory approval for its CAR-T therapy CTL019 in the US, Novartis has now turned its attention to Europe.

  • Novartis moves swiftly with lymphoma filing for CAR-T Kymriah Novartis moves swiftly with lymphoma filing for CAR-T Kymriah

    Novartis moves swiftly with lymphoma filing for CAR-T Kymriah. Will go up against Kite Pharma's Yescarta if approved. ... Just a few weeks after claiming the first approval for a CAR-T therapy, Novartis is trying to extend its lead by filing for a second

More from news
Approximately 4 fully matching, plus 32 partially matching documents found.

Latest Intelligence

  • No incentive for a cure No incentive for a cure

    These include Kymriah, the pioneering CAR-T cell therapy from Novartis, which demonstrated a remarkable 83% remission rate in children and young adults with B-cell precursor acute lymphoblastic leukaemia. ... One of the biggest questions with a curative

  • Can value-based healthcare take off and reach for the skies? Can value-based healthcare take off and reach for the skies?

    CAR-T cell therapy for children with B-cell ALL. ... costs. It was then backed with a ‘no response-no payment’contract. It has also struck novel reimbursement packages with its heart failure therapy Entresto and its psoriasis treatment Cosentyx.

  • The rise of real-world evidence The rise of real-world evidence

    Novartis secured such an outcome-based model for its CAR-T therapy Kymriah. ... Spark Therapeutics has a similar arrangement for its gene therapy. These agreements make real-world efficacy a requirement for full payment for a drug.

  • Deal Watch January 2018

    Having terminated the development of its lead CAR-T therapy, JCAR015, early last year after several patient deaths in a phase II clinical trial in relapsed/refractory B-cell acute lymphoblastic ... Juno Therapeutics/ Celgene. CAR-T and TCR therapeutics

  • The gold standard of scientific evidence The gold standard of scientific evidence

    Additionally, RWE is being used to inform. creative drug pricing. When seeking coverage for Kymriah, a new CAR-T therapy, Novartis has an agreement with the Centers for Medicaid and Medicare

More from intelligence
Approximately 0 fully matching, plus 15 partially matching documents found.

Latest appointments

  • Celgene boosts CAR-T stake again with Bluebird Bio deal Celgene boosts CAR-T stake again with Bluebird Bio deal

    Mere weeks after completing its acquisition of CAR-T specialist Juno, Celgene has added to its cell therapy pipeline with another clinical-stage CAR-T candidate from Bluebird Bio. ... It could also receive additional, undisclosed milestones if the CAR-T

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
EY Life Sciences

Our global reach Against a backdrop of regulatory, digital, financial and global transformation, Life Sciences companies are finding integration and...

Latest intelligence

No Voice, No Choice
Adelphi Research UK’s insights help to campaign for change in the Mental Health Act...
Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...

Infographics